GR1803-002: GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - May 28, 2026 - P2 | N=116 | Active, not recruiting | Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Aug 2026 ➔ May 2027
Enrollment closed • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology
|